Trius Therapeutics, Inc.  

(Public, NASDAQ:TSRX)   Watch this stock  
Find more results for TSRX
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -1.60
Shares 48.27M
Beta     -
Inst. own 59%

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin -1524.56% -198.37%
Operating margin -1466.69% -210.53%
EBITD margin - -208.10%
Return on average assets -96.35% -75.21%
Return on average equity -124.37% -101.10%
Employees 90 -
CDP Score - -


65 Hayden Avenue
United States - Map
+1-781-8608660 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Trius Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company is developing tedizolid phosphate, a new, novel antibiotic, for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus, or MRSA. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, or ABSSSI, and pneumonia, and for other indications. ABSSSI is the current classification for complicated skin and skin structure infections. In addition, the Company is discovering antibiotics for infections caused by Gram-negative bacteria using the structure based discovery platform. As on December 2012, the Company completed enrollment in the second Phase III clinical trial, the ESTABLISH 2 (TR701-113) study, of the intravenous to oral transition therapy for the treatment of ABSSSI.